PEAK6 Investments’s Fulgent Genetics FLGT Stock Holding History

PEAK6 Investments’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-103	Closed	-$2.23K	–	3819
2024 Q1	$2.23K	Sell	103 -17,735	-99%	-$440K	﹤0.01%	3820
2023 Q4	$516K	Buy	17,838 +17,470	+4,747%	+$467K	﹤0.01%	2586
2023 Q3	$9.84K	Sell	368 -13,997	-97%	-$478K	﹤0.01%	3818
2023 Q2	$532K	Sell	14,365 -3,730	-21%	-$130K	﹤0.01%	2168
2023 Q1	$565K	Sell	18,095 -24,037	-57%	-$774K	﹤0.01%	2291
2022 Q4	$1.25M	Buy	42,132 +21,541	+105%	+$771K	0.01%	1734
2022 Q3	$785K	Buy	20,591 +6,226	+43%	+$312K	﹤0.01%	2434
2022 Q2	$532K	Buy	14,365 +9,280	+182%	+$510K	﹤0.01%	3759
2022 Q1	$317K	Buy	+5,085	New	+$335K	﹤0.01%	3528
2021 Q4	–	Sell	-440	Closed	-$38.7K	–	5321
2021 Q3	$40K	Buy	+440	New	+$40K	﹤0.01%	4669

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PEAK6 Investments's FLGT Position: Q2 2024 in Review

PEAK6 Investments sold out of Fulgent Genetics (FLGT) in Q2 2024, closing a stake of 103 shares — an estimated $2.23K sold.

PEAK6 Investments first reported a position in FLGT in Q3 2021 and held it in 10 quarters. The position peaked at $1.25M in Q4 2022. 173 funds tracked by Wall St. Rank hold FLGT as of Q2 2024.

PEAK6 Investments reported no remaining Fulgent Genetics position as of Q2 2024 after selling out during the quarter.
PEAK6 Investments sold 103 Fulgent Genetics shares in Q2 2024, an estimated $2.23K.
PEAK6 Investments first reported a position in Fulgent Genetics in Q3 2021 and held it in 10 quarters.
PEAK6 Investments's Fulgent Genetics position peaked at $1.25M in Q4 2022.
173 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2024.

Based on PEAK6 Investments's 13F filing for Q2 2024, filed 14 Aug 2024.